Medical therapy for pediatric inflammatory bowel disease

Current Gastroenterology Reports

Volumn 14, Issue 2, 2012, Pages 166-173

  Sherlock, Mary E ^a   Griffiths, Anne M ^b  

^a MCMASTER CHILDREN S HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Adalimumab; Biologic; Crohn's disease; Enteral nutrition; Immunomodulator; Inflammatory bowel disease; Infliximab; Pediatric; Pediatric inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VSL3;

ARTICLE; CHILD; CHILD CARE; CHILD GROWTH; CLINICAL PRACTICE; COLON RESECTION; CROHN DISEASE; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SURVEILLANCE PROGRAM; ENTERIC FEEDING; ENTERITIS; EVIDENCE BASED MEDICINE; HEPATOSPLENIC T CELL LYMPHOMA; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; ILEOANAL ANASTOMOSIS; LATENT TUBERCULOSIS; LISTERIOSIS; LOW DRUG DOSE; MEDICAL DECISION MAKING; MULTICENTER STUDY (TOPIC); PATIENT SAFETY; PATIENT SELECTION; PHENOTYPE; PRACTICE GUIDELINE; PSORIASIS; RELAPSE; REMISSION; T CELL LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; PATIENT SELECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861101026     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0249-5     Document Type: Article

References (48)

1. Benchimol E, Fortinsky K, van der Heuvel M, van Limbergen J, Griffiths AM. Epidemiology of pediatric IBD: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423-39.
2. Braegger C, Balabbeni P, Rogler D, et al. Epidemiology of inflammatory bowel disease: is there a shift towards onset at an earlier age? J Pediatr Gastro Nutr. 2011;53:141-4.
3. Imielinski M, Baldassano R, Griffiths AM, et al. Common variants at 16p11 implicate IL-27 in childhood-onset inflammatory bowel disease. Nat Genet. 2009;41:1335-40.
4. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033-45.
5. Levine A, Griffiths AM, Markowitz J, et al. Pediatric Modification of the Montreal Classification for Inflammatory Bowel Disease - the Paris Classification. Infl Bowel Dis Inflamm Bowel Dis. 2011;17:1314-21.
6. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135(4):1114-22.
7. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135(4):1106-13.
8. Walters TD, Griffiths AM. Mechanisms of Disease: growth impairment in paediatric Crohn's disease. Nature Rev Gastroenterol Hepatol. 2009;6:513-23.
9. Wilson D, Thomas A, Croft N, et al. Systematic Review of the Evidence Base for the Medical Treatment of Paediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2010 Jan 13.
10. Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol. 2004;18(3):509-23. (Pubitemid 38667463)
11. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008 Jul 16;(3)(3):CD000296.
12. Levine A. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: A randomized placebo-controlled trial. Inflamm Bowel Dis. 2009;15:1055-61.
13. Buchanan E, Gaunt WW, Cardigan T, et al. The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009;30(5):501-7.
14. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4(6):744-53. (Pubitemid 43825808)
15. Day AS, Whitten KE, Sidler M, Lemberg DA. Systematic review: nutritional therapy in paediatric Crohn's disease. Aliment Pharmacol Ther. 2008;27(4):293-307.
16. Leach ST, Mitchell HM, Eng WR, Zhang L, Day AS. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. Aliment Pharmacol Ther. 2008;28(6):724-33.
17. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132(3):863-73. (Pubitemid 46454266)
18. Hyams J,GriffithsAM, Markowitz J et al Induction andMaintenance Adalimumab for Moderate to Severe Crohn's Disease in Children: A Randomized Double-Blind Trial. Gastroenterology 2011;140:S90.
19. Hanauer SB, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002;359:1451-9.
20. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357(3):228-38. (Pubitemid 47080387)
21. Borelli O, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis. 2004;36:342-7.
22. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829-38. (Pubitemid 351650483)
23. D'Haens G, et al. Early combined immunesuppression or conventional management in recently diagnosed patients with Crohn's disease: an open randomized trial. Lancet. 2008;371:660-7. (Pubitemid 351284485)
24. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221-9.
25. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119 (4):895-902.
26. Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol. 2007;102(12):2804-12. (Pubitemid 350179322)
27. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis. 2006;12(11):1053-7. (Pubitemid 44665475)
28. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4(10):1248-54. (Pubitemid 44512213)
29. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383-95.
30. Schnitzler F, et al. Longterm outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a singlecentre cohort. Gut. 2009;58:492-8.
31. deRidder L, et al. Infliximab Dependency in Pediatric Crohn's Disease: Longterm follow-up of an Unselected Cohort. Inflamm Bowel Dis. 2008;14:353-8.
32. Shale M, et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008;57:1639-41.
33. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale. Inflamm Bowel Dis. 2007;13(8):1024-30. (Pubitemid 47309975)
34. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36-41.e1.
35. Melmud G, et al. The appropriateness of concomitant immunemodulators with anti-TNF agents for Crohn's disease: one size does not fit all. Clin Gastro Hepatol. 2010;8:655.
36. Maini RN, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-63. (Pubitemid 28459913)
37. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn disease. Inflamm Bowel Dis. 2007;13:1-7.
38. Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33 (8):946-53.
39. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133(2):423-32. (Pubitemid 47193130)
40. Zeisler B, Lerer T, Markowitz J et al. Outcome following aminosalicylate therapy in children newly diagnosed with ulcerative colitis: a prospective multi-center registry experience.
41. Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastro Hepatol. 2006;4(9):1118-23. (Pubitemid 44311638)
42. Hyams J, Damaraju L, Blank M et al. A randomized multi-center open label phase 3 study to evaluate the safety and efficacy of infliximab in pediatric patients with moderate to severe ulcerative colitis. Clin Gastro Hepatol 2011. doi:10.1016/j.cgh.2011.11.026.
43. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104 (2):437-43.
44. Hyams JS, Lerer T, Mack D, et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol. 2011;5:981-7.
45. Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, outcomes, and optimal timing for second line therapy. Gut. 2008;57:1-10.
46. Turner D, Griffiths A. Acute severe paediatric ulcerative colitis: a systematic review. Inflamm Bowel Dis. 2011;17:440-9.
47. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138(7):2282-91.
48. Turner D, Travis SP, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastro. 2011;106:574-88.